You are here

Sarcura (AU) and imec to advance gene and cell therapy

In the pursuit of an effective cure for cancer, every small victory counts. Yet, the new partnership between Sarcura and imec is anything but small. The Austrian tech start-up announced a collaboration with imec, Flanders’ world-leading nanotech research center, which aims to move gene and cell therapy forward. “We share the same vision of cross-industry innovation,” says Daniela Buchmayr, CEO of Sarcura.

Defying the odds

Transformative cell therapies, which use a patient’s own living immune cells to attack malignant tissue, constitute a promising new cancer treatment. However, due to its diverse and individualized nature, cell therapy has long been a bottleneck for the biotech industry, which remains committed to established generic biomanufacturing concepts at high volume. That’s where Sarcura comes into play. This newly founded early-stage technology company is developing an instrument platform for the GMP manufacturing of autologous cell therapies.

Innovation through collaboration

Crucial in the development of Sarcura’s automated cell therapy manufacturing solution is its collaboration with imec, one of Europe’s top research centers for start-up support. Together with this leading expert in silicon technologies and nanoelectronics, the Austrian firm will work on an integrated, silicon photonics cytometer for automated cell separation. According to Daniela Buchmayr, CEO of Sarcura, this solution, unleashed at manufacturing scale, will open new opportunities for industrial cell processing.

In imec, we found a trusted partner that shares the same vision of using cross-industry innovation to tackle manufacturing challenges in cell and gene therapy.

Daniela Buchmayr
CEO of Sarcura

On the verge of a breakthrough

For imec, this partnership fits in well with its ambition to connect to the cell and gene therapy ecosystem. “The use of silicon technology allows extreme miniaturization, as well as microfluidic parallelization and scalable photonic integration of optical cell measurements,” explains Liesbet Lagae, life sciences R&D director and fellow at imec. “This allows the expert team to build compact high-throughput modules that can inspect every single cell and handle billions of cells.”

Our collaboration with Sarcura will help make highly potent cell and gene therapies affordable and accessible.

Liesbet Lagae
life sciences R&D director and fellow at imec

More info

Sarcura
Reported by
www.imec-int.com
20 May 2021

More news about Flanders?

  • Regular updates
  • No spam

Interested in doing business in Flanders?

Let us help you!

  • We can introduce you to other companies, banks and regulators
  • We organize site visits to real estate locations
  • We assist with all legal aspects of setting up a business
  • We're an official government agency
  • Our services are completely free
  • We are a team of international experts

Receive our handbook to growing your business in Flanders

  • It's completely free.
  • Get an overview of all incentives relevant to your company.
  • Tax system explained in-depth.
  • Learn how to set up your business quickly.
  • Discover the benefits of Flanders (in addition to the chocolate).

In addition to the ebook, I agree to receive one or two follow-up emails